CeriBell, Inc.
CeriBell, Inc. (CBLL) Financial Performance & Income Statement Overview
Review CeriBell, Inc. (CBLL) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
CeriBell, Inc. (CBLL) Income Statement & Financial Overview
Review CeriBell, Inc. CBLL income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $20.49M | $18.53M | $17.20M | $14.86M |
| Cost of Revenue | $2.48M | $2.30M | $2.18M | $2.11M |
| Gross Profit | $18.007M | $16.24M | $15.01M | $12.75M |
| Gross Profit Ratio | $0.88 | $0.88 | $0.87 | $0.86 |
| R&D Expenses | $4.25M | $3.91M | $3.40M | $3.13M |
| SG&A Expenses | $27.97M | $25.21M | $21.55M | $18.07M |
| Operating Expenses | $32.21M | $29.12M | $24.95M | $21.19M |
| Total Costs & Expenses | $34.70M | $31.42M | $27.13M | $23.30M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$471000.00 | $499000.00 | $530000.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $364000.00 | $243000.00 | $267000.00 |
| EBITDA | -$14.21M | -$11.71M | -$9.64M | -$8.18M |
| EBITDA Ratio | -$0.69 | -$0.63 | -$0.56 | -$0.55 |
| Operating Income | -$14.21M | -$12.88M | -$9.94M | -$8.44M |
| Operating Income Ratio | -$0.69 | -$0.70 | -$0.58 | -$0.57 |
| Other Income/Expenses (Net) | $1.43M | $308000.00 | -$480000.00 | -$287000.00 |
| Income Before Tax | -$12.78M | -$12.58M | -$10.42M | -$8.73M |
| Income Before Tax Ratio | -$0.62 | -$0.68 | -$0.61 | -$0.59 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.78M | -$12.58M | -$10.42M | -$8.73M |
| Net Income Ratio | -$0.62 | -$0.68 | -$0.61 | -$0.59 |
| EPS | -$0.36 | -$0.40 | -$0.31 | -$1.59 |
| Diluted EPS | -$0.36 | -$0.40 | -$0.31 | -$1.59 |
| Weighted Avg Shares Outstanding | $35.88M | $31.21M | $34.02M | $5.51M |
| Weighted Avg Shares Outstanding (Diluted) | $35.88M | $31.21M | $34.02M | $5.51M |
Over the past four quarters, CeriBell, Inc. demonstrated steady revenue growth, increasing from $14.86M in Q2 2024 to $20.49M in Q1 2025. Operating income reached -$14.21M in Q1 2025, maintaining a consistent -69% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$14.21M, reflecting operational efficiency. Net income dropped to -$12.78M, with EPS at -$0.36. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan